Global Pneumonia Therapeutics Market Size study & Forecast, by Therapeutics (Prevention Vaccines and Treatment Drugs), by Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), and by Age Group (Pediatric, Adult, and Geriatric) and Regional

Global Pneumonia Therapeutics Market Size study & Forecast, by Therapeutics (Prevention Vaccines and Treatment Drugs), by Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), and by Age Group (Pediatric, Adult, and Geriatric) and Regional Analysis, 2022-2029

Global Pneumonia Therapeutics Market is valued approximately USD 13.24 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2022-2029. Pneumonia is a type of acute respiratory infection that inflames the air sacs in one or both lungs caused by bacteria, viruses, or fungi. The signs and symptoms of Pneumonia include cough, with greenish, yellow, and bloody mucus, fever, sweating, shortness of breath, rapid, shallow breathing, and stabbing chest pain among others. The increasing incidences of pneumonia and growing unmet clinical needs as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to UNICEF – as of 2019, globally around 700,000 children under five lost their lives every year, accounting for around 2,000 deaths every day. In addition, South Asia (2,500 cases per 100,000 children) is the most affected region followed by West and Central Africa (1,620 cases per 100,000 children). Also, rising healthcare spending in developing regions and growing number of R&D activities in pharmaceuticals sector would create lucrative growth prospectus for the market over the forecast period. However, a high treatment cost and lack of awareness towards preventive vaccines impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pneumonia Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of revenue due to presence of leading pharmaceutical giants as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population and increasing prevalence of pneumonia in children in the region.

Major market player included in this report are:
Abbott Laboratories
Bayer AG
Eli Lilly & Company
GlaxoSmithKline PLC.
Lupin Pharmaceuticals, Inc.
Merck KGAA
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceuticals Industries Limited.

Recent Developments in the Market:
In December 2020, India based Serum Institute of India launched first indigenous vaccine for pneumonia. The new vaccines would be provided for children throughout the world with the help of UNICEF network.

In July 2021, US based Merck received the U.S. Food and Drug Administration (FDA) approval for its new VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) intended for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.


Global Pneumonia Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered

Therapeutics, Distribution Channel, Age Group, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics
Prevention Vaccines
Treatment Drugs
By Distribution Channel
Hospitals
Pharmaceutical Stores
Other
By Age Group
Pediatric
Adult
Geriatric

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned

Abbott Laboratories
Bayer AG
Eli Lilly & Company
GlaxoSmithKline PLC.
Lupin Pharmaceuticals, Inc.
Merck KGAA
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceuticals Industries Limited.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.